MD35Y - Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland - Google Patents

Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Info

Publication number
MD35Y
MD35Y MDS20080030A MDS20080030A MD35Y MD 35 Y MD35 Y MD 35Y MD S20080030 A MDS20080030 A MD S20080030A MD S20080030 A MDS20080030 A MD S20080030A MD 35 Y MD35 Y MD 35Y
Authority
MD
Moldova
Prior art keywords
situ
examination
detected
risk
determined
Prior art date
Application number
MDS20080030A
Other languages
Romanian (ro)
Inventor
Vasile Jovmir
Simona CHIABURU
Natalia Rotaru
Original Assignee
Vasile Jovmir
Simona CHIABURU
Natalia Rotaru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasile Jovmir, Simona CHIABURU, Natalia Rotaru filed Critical Vasile Jovmir
Priority to MDS20080030A priority Critical patent/MD35Z/en
Publication of MD35Y publication Critical patent/MD35Y/en
Publication of MD35Z publication Critical patent/MD35Z/en

Links

Landscapes

  • Apparatus For Radiation Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Inventia se refera la medicina, in special la oncologie si poate fi utilizata pentru aprecierea riscului dezvoltarii carcinomului neinvaziv in situ al glandei mamare pentru stabilirea tratamentului. Esenta inventiei include efectuarea investigatiilor clinice, examenului ultrasonografic si mamografic, efectuarea tomografiei computerizate. Daca clinic nu se depisteaza semne obiective sau subiective sau se determina prezenta eliminarilor seroase din ductul glandei mamare, la examenul ultrasonografic se depisteaza schimbari difuze in tesutul glandular, la examenul mamografic se determina pana la 5 microcalcifieri la 1 cm2, dupa Le Gal tipul I sau II, dupa Clasificarea Colegiului American de Radiologie (CAR) 1, 2 sau 3 si la tomografia computerizata fara patologie si lipsa nodulilor limfatici regionali suspecti de metastazare, se apreciaza un risc minor de dezvoltare a carcinomului neinvaziv in situ. Daca clinic sunt semne de inflamatie sau induratie cu eliminari seroase sau sero-sangvinolente din ductul glandei mamare, la examenul ultrasonografic se depisteaza fibroadenomatoza localizata, suspectie la prezenta de microcalcifieri, la examenul mamografic se determina pana la 10 microcalcifieri la 1 cm2, dupa Le Gal tipul III, dupa CAR 4 si la tomografia computerizata se determina induratie, microcalcifieri pana la 10 la 1 cm2, papilom intraductal si lipsa nodulilor limfatici regionali suspecti de metastazare, se apreciaza risc mediu de dezvoltare a carcinomului neinvaziv in situ, iar daca clinic se determina induratie sau formatiune tumorala cu eliminari sangvinolente, la examenul ultrasonografic se depisteaza fibroadenomatoza localizata sau o formatiune cu microcalcifieri, la examenul mamografic se determina mai mult de 10 microcalcifieri la 1 cm2, dupa Le Gal tipul IV-V, dupa CAR 5 si la tomografia computerizata se determina tumoare cu densitate scazuta sau fibroadenomatoza localizata, papiloame intraductale multiple, microcalcifieri mai mult de 10 la 1 cm2 si lipsa nodulilor limfatici regionali suspecti de metastazare, se apreciaza risc major de dezvoltare a carcinomului neinvaziv in situ. Revendicari: 1The invention relates to medicine, in particular to oncology and can be used to assess the risk of developing non-invasive carcinoma in situ of the mammary gland to establish treatment. The essence of the invention includes performing clinical investigations, ultrasonographic and mammographic examination, performing computed tomography. If clinical or objective signs are not detected or the presence of serous eliminations in the duct of the mammary gland is detected, diffuse changes in the glandular tissue are detected at the ultrasonographic examination, at the mammographic examination it is determined up to 5 microcalcis ie 1 cm2, after Le Gal type I or II, after the Classification of the American College of Radiology (CAR) 1, 2 or 3 and on the computed tomography without pathology and the lack of the regional lymph nodes suspected of metastasis, a minor risk of developing non-invasive carcinoma in situ is evaluated. If clinically there are signs of inflammation or induration with serous or sero-bloody eliminations from the duct of the mammary gland, localized fibroadenomatosis is detected at the ultrasonographic examination, suspected in the presence of microcalc mean, at the mammographic examination it is determined up to 10 microcalcium at 1 cm2, after Le Gal type III, after CAR 4 and computed tomography, induration is determined, microcalc ie up to 10 to 1 cm2, intraductal papilloma and lack of regional lymph nodes suspected of metastasis, the average risk of developing non-invasive carcinoma in situ is assessed, and if clinically determined induration or tumor formation with bloody eliminations, ultrasound examination localized fibroadenomatosis or microcalcial formation is detected, mammographic examination determines more than 10 microcalcifications, ie 1 cm2, after Le Gal type IV-V, after CAR 5 and on computed tomography tumors with low density or fibroadenomatosis are determined of localized, multiple intraductal papillomas, microcalc ie more than 10 to 1 cm2 and lack of regional lymph nodes suspected of metastasis, is considered a major risk of developing non-invasive carcinoma in situ. Claimant: 1

MDS20080030A 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland MD35Z (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Publications (2)

Publication Number Publication Date
MD35Y true MD35Y (en) 2009-06-30
MD35Z MD35Z (en) 2010-01-31

Family

ID=40942312

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Country Status (1)

Country Link
MD (1) MD35Z (en)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD106C2 (en) * 1993-11-12 1995-06-30 Онкологический Институт Республики Молдова Method of treatment for mamma cancer
MD446G2 (en) * 1995-07-07 1996-11-30 Онкологический Институт Республики Молдова Method for mamma cancer treatment
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
MD798G2 (en) * 1996-11-15 1998-05-31 Онкологический Институт Республики Молдова Method of the mamma cancer treatment
MD962G2 (en) * 1997-07-24 1998-12-31 Онкологический Институт Республики Молдова Method for radical mastectomy
EA003256B1 (en) * 1997-08-29 2003-02-27 Байоджен, Инк. METHOD FOR TREATING MALIGNANT TUMOR BY IN VIVO GENE THERAPY WITH USE OF GENES ENCODING INTERFERON-beta
ID27614A (en) * 1997-11-28 2001-04-12 Masayuki Matsuura METHOD AND RADAS FOR WAVE THERAPY
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
MD1630G2 (en) * 1999-06-04 2001-09-30 Онкологический Институт Республики Молдова Method of radical mastectomy in breast cancer
UA74798C2 (en) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
MD1569G2 (en) * 1999-12-17 2001-06-30 Онкологический Институт Республики Молдова Method of treatment of breast canceeeer in the preoperation period
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015446D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives
MD2849G2 (en) * 2005-05-16 2006-04-30 Василе ЖОВМИР Method of mammary cancer treatment to patients of old age
MD3248G2 (en) * 2006-06-30 2007-09-30 Василе ЖОВМИР Method of mammary cancer treatment
MD3671G2 (en) * 2007-11-02 2009-09-30 Онкологический Институт Республики Молдова Method of subtotal mastectomy in the mammary upper dial cancer
MD3772G2 (en) * 2008-05-12 2009-07-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Method for treating mammary cancer with metastases
  • 2008

Also Published As

Publication number Publication date
MD35Z (en) 2010-01-31

Similar Documents

Publication Publication Date Title
Liu et al. Application of CT texture analysis in predicting histopathological characteristics of gastric cancers
Radhakrishna et al. Role of magnetic resonance imaging in breast cancer management
DeFilippis et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues
Skuladottir et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark
Cho et al. Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma
Adamovich et al. Ductal carcinoma in situ with microinvasion
Oliveira et al. Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods
Simsir et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status
Hoseini et al. An overview of clinical and pathological characteristics and survival rate of colorectal cancer in Iran
Guimarães et al. Front pattern of invasion in squamous cell carcinoma of the penis: new prognostic factor for predicting risk of lymph node metastases
Tsuji et al. Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis
Potretzke et al. Is ureteroscopy needed prior to nephroureterectomy? An evidence-based algorithmic approach
Innos et al. Subsite-and stage-specific colorectal cancer trends in Estonia prior to implementation of screening
Tabár et al. The challenging imaging and histopathologic features of diffusely infiltrating breast cancer
Ampil et al. Carcinoma of the axillary tail of Spence: a case series
Kunlabut et al. Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis
McLaughlin et al. The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now?
Song et al. Prediction of inflammatory breast cancer survival outcomes using computed tomography-based texture analysis
Gao et al. Enhancing the screening efficiency of breast cancer by combining conventional medical imaging examinations with circulating tumor cells
Matoori et al. Contrast-enhanced CT density predicts response to sunitinib therapy in metastatic renal cell carcinoma patients
MD35Y (en) Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland
Mitsuhashi et al. Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients
Valkova et al. Primary epidemiological evaluation of the effectiveness of the All-National Dispensarization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry
Dawood et al. Clinical aspect of inflammatory breast cancer: Diagnosis, criteria, controversy
Yoon et al. Outcomes of ductal carcinoma in situ according to detection modality: a multicenter study comparing recurrence between mammography and breast US

Legal Events

Date Code Title Description
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)
MM4Y Short-term patent definitely lapsed due to non-payment of fees